Recruiting
SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients
cyclodiode versus trabeculectomy with MMC in pseudophakic patients.
ClinicalTrials.gov IDNCT07152132
PhaseNA
Enrollment50
SponsorMinia University
Age40 Years
SexALL
Conditions studied
Glaucoma, Open Angle
About this study
cyclodiode versus trabeculectomy with MMC in pseudophakic patients.
Interventions
- Procedure: Trabeculectomy — Trabeculectomy with mitomycin c application
- Procedure: Slow coagulation trans-scleral cyclophotocoagulation — Slow coagulation trans-scleral cyclophotocoagulation
Primary outcomes
- evaluate and compare the amount of iop reduction between SC-TSCPC and trabeculectomy with MMC in the management of medically uncontrolled OAG in pseudophakic eyes. (6 months)
- evaluate and compare the degree of safety of SC-TSCPC versus trabeculectomy with MMC in the management of medically uncontrolled OAG in pseudophakic eyes. (6 months)
Eligibility information
Inclusion Criteria:
* 1\. Patients above 40 years old.
2\. POAG who underwent previous uncomplicated cataract surgery with intraocular lens implantation.
3\. Pseudophakic patients with medically uncontrolled glaucoma in spite of the use of two anti-glaucoma medications or intolerance to medical therapy.
4\. Visual field defects in both the superior and inferior hemi-fields outside the central 5 degrees of fixation.
5\. Mean deviation on perimetry ranges between -6 dB and -12 dB
Exclusion Criteria:
* 1\. Patients with history of previous glaucoma surgery. 2. Patients who have used topical steroids within the last three months. 3. Patients with significant media opacity, such as corneal opacity, that obstructs fundoscopic examination.
4\. Patients with ocular diseases as uveitis. 5. Patients with severe ocular surface disorders as ocular cicatricial pemphigoid.
6\. Aphakic patients. 7. Ocular interventions apart from YAG posterior capsulotomy.
Study locations
- Minia University Hospital, Minya, 61111 Egypt
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.